Patient-reported outcomes of laparoscopic magnetic sphincter augmentation for gastro-oesophageal reflux disease

IntroductionGastro-oesophageal reflux disease (GORD) is a chronic progressive disease, associated with substantial clinical and economic burden.Proton pump inhibitors (PPIs) are considered first-line treatment; however, there are concerns around the long-term impact of their usage. Surgicaltreatment with Nissen fundoplication can be considered but, because of the potential side effects, few patients undergo surgery and there remains asubstantial therapeutic gap within the current treatment pathway. Laparoscopic magnetic sphincter augmentation (MSA) using the LINX (R) device is analternative surgical approach.MethodsThe objective of this study was to investigate patient-reported outcomes following laparoscopic MSA surgery using the LINX (R) device in a UKsetting. A retrospective questionnaire obtained data regarding postoperative symptoms, medication use and patient satisfaction.ResultsOut of 131 patients surveyed, 97 responses were received, with a minimum follow-up time of 1 year. In those who reported heartburn andregurgitation preoperatively, improvement was reported in 93% (84/90) and 90% (86/96) of patients, respectively. Eighty-eight per cent (73/83) ofpatients were able to completely stop or reduce their medication by at least 75%. Seventy-seven per cent (73/95) of patients were"very satisfied"or"satisfied".ConclusionsThis study is the first to present patient-reported outcomes of MSA using the LINX (R) device for patients with GORD in the UK. It demonstratesthat the device has favourable outcomes and could effectively bridge the current therapeutic gap that exists between PPI medication and Nissenfundoplication.